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SUMMARY. The purpose of this study was the economic
evaluation of short-duration treatments of chronic hepatitis
B (CHB) and longer duration antiviral treatment for up to
5 years. Two 10-health state Markov models were developed
for hepatitis B e antigen (HBeAg)-positive and HBeAg-neg-
ative CHB patients respectively. The perspective of this eco-
nomic evaluation was the Singapore healthcare system and
CHB patient. The models followed cohorts of HBeAg-positive
and HBeAg-negative CHB patients, respectively, over a per-
iod of 40 years, by which time the majority of the cohorts
would have died if left untreated. Costs and beneﬁts were
discounted at 5% per annum. Annual rates of disease pro-
gression and the magnitude of treatment effects were ob-
tained from the literature, with a focus on data obtained in
Asian patients and meeting the criteria for therapy as des-
cribed in internationally recognized management guidelines.
Short-course therapy with a-interferon, or 1-year treatment
with pegylated interferon a-2a, lamivudine or adefovir had
limited impact on disease progression. In contrast, treatment
of CHB with antiviral therapy for 5 years substantially de-
creased the rate of disease progression. Treatment with
lamivudine for 1-year is highly cost-effective compared with
no treatment of CHB but has limited effect on reducing the
rate of disease progression. Compared with 1-year treatment
with lamivudine, sequential antiviral therapies for up to
5 years (i.e. lamivudine plus adefovir on emergence of
lamivudine resistance or adefovir plus lamivudine on emer-
gence of adefovir resistance) are highly cost-effective by
international standards. These conclusions are robust to
uncertainties in model inputs and are consistent with the
ﬁndings of other recently published studies.
Keywords: a-interferon, adefovir, chronic hepatitis B, cost-
effectiveness, lamivudine, pegylated interferon a-2a.
INTRODUCTION
Burden of chronic hepatitis B (CHB)
Worldwide more than 350 million people are chronically
infected with hepatitis B virus (HBV) and at increased risk of
death from cirrhosis of the liver and hepatocellular carci-
noma (HCC) [1].
Chronic hepatitis B is characterized by elevated serum
aminotransferase (ALT) levels, high or ﬂuctuating levels of
serum HBV-DNA and active liver disease on biopsy [2].
Persistently elevated serum HBV-DNA levels are associated
with increased long-term risk of cirrhosis, HCC and liver
failure [3–5].
Persons with CHB may have hepatitis B e antigen (HBeAg)
or antibodies to HBeAg (anti-HBe) in their sera. HBeAg
seroconversion is associated with clearance of HBeAg from
serum and with the appearance of anti-HBe. In persons who
are HBeAg-positive, spontaneous HBeAg seroconversion can
occur, often accompanied by a transient elevation in ALT
levels. After HBeAg seroconversion, most persons have per-
sistently normal ALT levels and suppressed levels of HBV-
DNA, usually <10
3 copies/mL. However, almost 20% of
patients have active liver disease following spontaneous
HBeAg-seroconversion, due to the development of mutations
in the precore stop codon or core promoter region. HBeAg-
Abbreviations: ALT, aminotransferase; CC, compensated cirrhosis;
CHB, chronic hepatitis B; DCC, decompensated cirrhosis; GNI, Gross
National Income; HBeAg, hepatitis B e antigen; HBV, hepatitis B
virus; HCC, hepatocellular carcinoma; HR QoL, health-related
quality of life; ICERs, incremental cost-effectiveness ratios; PEG-IFN,
pegylated interferon; PPP, purchasing power parity; QALY, quality
adjusted life year.
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an important and increasingly prevalent form of CHB, often
associated with certain HBV genotypes (B, C and D but not A
or G) [2]. More than 95% of HBV infections in Asia-Paciﬁc
countries are HBV genotypes B or C, explaining the high
prevalence of HBeAg-negative CHB in this region.
Chronic hepatitis B remains an important public health
problem in Singapore. Although the incidence of HBV infec-
tionisdecreasing, asaresultofthecompulsory vaccinationof
babies born to infected mothers, nevertheless, between
160 000 and 230 000 Singaporeans were chronically infec-
ted as of 2001 [6]. The annual healthcare costs for the year
2003 of managing CHB, compensated cirrhosis (CC), decom-
pensated cirrhosis (DCC) and HCC,were estimated by Li et al.,
2004 [6]. Direct healthcare costs were classiﬁed in terms of
outpatient consultations, inpatient admissions, antiviral drug
treatment, other medications, laboratory tests, imaging and
procedures. Lost income andlostproductivity fromillness will
be additional indirect costs of CHB for the population. The
annual costof treatmentincreases dramatically asthe disease
progresses from CC to DCC or HCC respectively (Fig. 1).
Asian-Paciﬁc guidelines for the management of CHB
The Asia-Paciﬁc consensus guidelines (2005) [7] on the
management of CHB state: … sustained viral suppression is
the key to the reduction or prevention of hepatic injury and
disease progression. Therefore, the primary goal of treatment
for CHB is to eliminate or permanently suppress HBV. The
ultimate long-term goal of therapy is to prevent hepatic de-
compensation, to reduce or prevent progression to cirrhosis
and/or HCC, and to prolong survival.
Current treatment options
Conventional interferon-a has been used in the treatment of
CHB for many years. Treatment is administered by subcu-
taneous injection, at a dosage of 5–10 MU three times a
week for 4–6 months. Predictors of a nonresponse to inter-
feron-a include Asian ethnicity, childhood infection, HBeAg-
negative CHB, high serum HBV-DNA levels and low serum
ALT levels [8].
Pegylated interferon a-2a is administered by subcutaneous
injection (180 lg) once-weekly for 48 weeks. Although
pegylated interferon has more antiviral efﬁcacy than con-
ventional interferon, the side-effect proﬁle appears to be
similar for both formulations [8].
For most patients with CHB, sustained viral suppression is
only attainable through long-term nucleos(t)ide analogue
therapy, as short-course therapies (4–12 months) only
achieve sustained responses in a minority of patients [7].
The disadvantage of long-term antiviral monotherapy is
the emergence of virological breakthrough secondary to the
selection of drug resistant mutants [9]. If resistance develops
in patients with compensated liver disease, an alternative
antiviral drug should be used to control the disease. The
patient can either have a second drug added or can be
switched to another drug with the option of a 1- or 2-month
overlap. If resistance emerges in patients with advanced liver
disease, a second drug should be added to continued ongoing
therapy with the ﬁrst drug [9].
Lamivudine was the ﬁrst nucleoside analogue to be li-
censed by the FDA for use in the chronic treatment of HBV
infection in 1998. It is well tolerated and results in HBV
suppression, ALT normalization and reduction of hepatic
inﬂammation, although resistant strains emerge when
lamivudine is used long term [10].
Adefovir dipivoxil is a new CHB antiviral treatment option
that is well tolerated and long-term therapy results in
incremental increase in rate of viral suppression below the
level of detection, ALT normalization and histological
improvement. In comparison with lamivudine, resistance to
adefovir is delayed and less frequent [11].
Mechanisms of resistance to lamivudine and adefovir have
distinct structural differences, and mutations conferring
cross-resistance to both drugs have not been reported [9].
Economic evaluation of CHB treatments
A new treatment is usually regarded as cost-effective when it
provides improved outcomes at an acceptable increased cost.
Cost-utility is a form of cost-effectiveness analysis that in-
volves the estimation of incremental cost per quality adjus-
ted life year (QALY). QALYs take into consideration quality
of life as well as quantity of life [12]. The Q in QALY is a
utility weight with values from 0 to 1. Death has a utility
value of 0 and perfect health has a utility value of 1. Cost per
QALY potentially allows for comparison between the cost-
effectiveness of treatments in different disease areas with
very different clinical outcome measures. This can facilitate
healthcare resource allocation decisions [12].
The decision rule that payers apply to judging whether a
new healthcare intervention is cost-effective is often not
stated explicitly. However, US health economists generally
agree that if an intervention can save 1 year of life for less
than US$ 50 000, it is cost-effective. Moreover, the UK
National Institute for Clinical Excellence recently stated that
the cost-effectiveness threshold is between £20 000 and
£30 000 (approximately US$ 36 000–54 000) [13].
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Fig. 1 Average cost per patient per disease state.
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752 L. F. Lacey & E. GaneAs US$ 1 ¼ approximately S$ 1.6, therefore a cost-effective
threshold of $50 000 is equivalent to approximately S$
80 000 in Singapore. However, adjusting for differences in
purchasing power parity (PPP) based Gross National Income
(GNI) per capita (2001) provides a cost-effectiveness
threshold in Singapore of approximately S$ 53 000
($80 000 · US$ 22 850/US$ 34 280) [14].
The purpose of this study was to establish the economic
evaluation of short-duration treatments of CHB and long-
duration antiviral treatments for up to 5 years. The context
for the economic evaluation was the Singapore healthcare
system and the healthcare needs of the CHB patient, in
which only direct costs were included. As a result, indirect
costs, such as lost productivity, from time off work due to
illness or premature death were excluded.
METHODS
Treatment scenarios
Three different treatment scenarios were investigated:
1. No treatment
2. Short-duration therapy with conventional interferon-a
(IFN) or 1-year treatment with pegylated interferon-a 2a
(Pegasys
TM), lamivudine or adefovir
3. Five-year antiviral treatment with adefovir or lamivu-
dine monotherapy, with switch to the alternative anti-
viral agent as rescue therapy upon emergence of
resistance (i.e. sequential monotherapy with either
lamivudine followed by adefovir as rescue for lamivu-
dine-resistance or adefovir followed by lamivudine as
rescue for adefovir-resistance). If resistance emerged in
patients with more severe disease (Metavir stage 3 or 4
ﬁbrosis), the alternative antiviral agent was added to
rather than switched with the initial agent and combi-
nation therapy with both adefovir plus lamivudine was
continued long term.
Patient populations and model design
The pharmaco-economic models comprise two 10-health
state Markov models, adapted from Crowley et al. (2000)
[15]. The HBeAg-positive CHB model (Fig. 2a) included
equal numbers of male and female patients from Singapore;
the average patient age at start of treatment was 30 years
[15,16]. HBeAg-seroconversion is the criterion for treatment
cessation. The HBeAg-negative CHB model (Fig. 2b) inclu-
ded patients with an average age of 40 years at start of
treatment, because of differences in age proﬁles between
HBeAg-positive and HBeAg-negative populations studied in
clinical trials (e.g. [17,18]). HBsAg-seroconversion is the
only criterion for treatment cessation in HBeAg-negative
CHB. Both models evaluate short-course treatments and
longer duration treatments up to 5 years, with duration of
follow-up of a total of 40 years, by which time the majority
of the cohort will have died, if left untreated. This enabled
long-term costs and outcomes to be determined.
Data sources
Disease progression rates in the absence of treatment were
derived mainly from a recent systematic literature review of
CHB disease progression in the Asia-Paciﬁc region and Africa
[19] and are given in Table 1.
Disease progression rates in the presence of treatment
were derived from studies investigating the effect of lami-
vudine treatment on disease progression and are given in
Table 1.
HBeAg-seroconversion rates in HBeAg-positive patients
were obtained from the published literature and are given in
Table 2a. HBV treatment response rates in HBeAg-negative
patients were obtained from the published literature and are
given in Table 2b.
Healthcare costs used are those applying in Singapore.
The healthcare costs for managing CHB, CC, DCC, HCC, for
the year 2003 were obtained from Li et al. (2004) [6]
(Fig. 1). Drug acquisition costs for CHB treatment alterna-
tives for the year 2005 are given in Table 3.
Health state utilities were adapted from Crowley et al.
(2000) [15] and are given in Table 4.
Treatment effects incorporated into the model
The following aspects of treatment effects were incorporated
into the model:
1. HBeAg-seroconversion or HBV response: In HBeAg-positive
CHB, HBeAg-seroconversion was used as a treatment-
stopping criterion. In HBeAg-negative CHB, HBV
response occurred when suppression of HBV viral load
occurred to non-detectable levels (<300–400 copies/mL).
Patients who underwent HBeAg-seroconversion or HBV
response were assumed to have a much reduced rate of
disease progression (limited to a 1% rate of progression to
CC per annum).
2. Seroreversion or loss of HBV response: Seroreversion (loss of
HBeAg-seroconversion and reoccurrence of active CHB)
could occur in HBeAg-positive CHB and loss of HBV
response (reappearance of detectable levels of HBV and
active CHB) could occur in HBeAg-negative CHB
(Fig. 2a,b).
3. Antiviral resistance: Emergence of resistance could occur
with time during antiviral therapies (Fig. 2a,b). The rates
of emergence of resistance for each treatment alternative
were assumed to be the same in HBeAg-positive and
HBeAg-negative CHB. Antiviral treatments were assumed
to be ineffective in patients who developed antiviral
resistance, unless the appropriate salvage therapy was
administered.
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progression: In addition to effects mediated by HBeAg-
seroconversion or HBV response, direct effects of treat-
ments on disease progression were factored in [16].
All short-duration treatments were assumed to have the
same magnitude of direct effect on reducing the rates of
disease progression as that achieved with lamivudine
administered for 1 year. For long-duration therapies, the
direct effects on disease progression lasted for the dur-
ation of therapy in those patients who did not develop
antiviral resistance (Table 1).
5. Effect of treatment on HR QoL as a result of side-effects: The
side-effects of interferon-a were assumed to have a
negative effect on health-related quality of life (HR QoL)
for the duration of treatment, reducing the CHB utility
during treatment [15]. This was also assumed to be the
case for pegylated interferon-a 2a but with an impact on
CHB utility 50% less than that of interferon-a. Lamivu-
dine and adefovir are well tolerated in CHB patients and
were assumed to have at least the same utility as
untreated CHB patients (Table 4).
Model outcomes
During annual cycles of the Markov models the proportion of
patients remaining alive in each health state and their
associated healthcare costs and QALYs were determined for
each treatment scenario. The total healthcare costs, life
years and QALYs over the 40-year time horizon of the model
were calculated for each treatment scenario, in the presence
and absence of discounting.
Model assumptions
There is a hierarchy of assumptions. The patient population
pertains to those CHB patients with ALT levels ‡2 · ULN; all
patients are in the CHB health-state at the outset and all are
Seroconversion
(a)
(b)
(non-active disease)
Chronic Hepatitis B (CHB) Resistant CHB
Compensated Cirrhosis (CC) Resistant CC
Decompensated Cirrhosis (DCC) Resistant DCC
Hepatocellular Carcinoma (HCC) Resistant HCC
Death
Note: the ‘resistant’ health states pertain to the presence of antiviral resistance and 
assumes lack of treatment effect for antiviral mono-therapy
HBV response (non-active disease)
Chronic Hepatitis B  (CHB) Resistant CHB
Compensated Cirrhosis (CC) Resistant CC
Decompensated Cirrhosis (DCC) Resistant DCC
Hepatocellular Carcinoma (HCC) Resistant HCC
Death
Note: the ‘resistant’ health states pertain to the presence of antiviral resistance and 
assumes lack of treatment effect for antiviral mono-therapy
After stopping 
treatment
During treatment
Fig. 2 Structure of (a) HBeAg-positive
chronic hepatitis B (CHB) Economic
Model; (b) HBeAg-negative CHB Econo-
mic Model.
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obtained or derived from the literature for this population.
However, for some model inputs the ALT status was either
elevated or unknown.
A list of all model assumptions is given in Appendix I.
Discounting
Costs and beneﬁts were discounted at 5% per annum,
although in year 1 there was no discounting. The
effect of discounting was investigated in the sensitivity
analyses.
Sensitivity analyses
Sensitivity analyses were carried out for the longer duration
CHB antiviral therapies (lamivudine plus adefovir as rescue
medication or adefovir plus lamivudine as rescue medica-
tion) administered for up to 5 years. One-way sensitivity
analyses were carried out by changing individual model
inputs over ranges of values obtained from the literature or
using pessimistic estimates for the magnitude of treatment
effectiveness. In addition, sensitivity analyses were also
carried out in which several model inputs were varied sim-
ultaneously.
Table 1 Disease progression rates for CHB derived from the literature and the effect of antiviral treatment on reducing the rates
of disease progression
Model input Treatment Estimate Source
Annual rate of progression from CHB to CC (HBeAg-
positive)
0.0260 From Lin X et al. 2005 [19]*
Annual rate of progression from CHB to CC (HBeAg-
negative)
0.0900 From de Franchis et al. 2003 [23]
% Decrease in annual rate of progression from CHB to
CC in absence of resistance
LAM 85.7% From Crowley et al. 2002 [16]
IFN & PEG-IFN 85.7% From Crowley et al. 2002 [16]
ADF 85.7% Assumption

% Decrease in annual rate of progression from CHB to
CC in presence of resistance
LAM; ADF 0.0000 Conservative assumption
Annual rate of progression from CHB to HCC 0.0066 From Lin X et al. 2005 [19]*
% Decrease in annual rate of progression from CHB to
HCC in presence of resistance
LAM; ADF 0.0000 Conservative assumption
Annual rate of progression from CC to DCC 0.0420 From Lin X et al. 2005 [19]*
% Decrease in annual rate of progression from CC to
DCC in absence of resistance
LAM 22.6% From Liaw et al. 2004 [5]

IFN & PEG-IFN 22.6% Assumption
ADF 22.6% Assumption

% Decrease in annual rate of progression from CC to
DCC in presence of resistance
LAM; ADF 0.0000 Conservative assumption
Annual rate of progression from CC to HCC 0.0430 From Lin X et al. 2005 [19]*
% Decrease in annual rate of progression from CC to
HCC in absence of resistance
LAM 17.6% Derived from Liaw et al. 2004 [5]
§
IFN & PEG-IFN 17.6% Assumption
ADF 17.6% Assumption

% Decrease in annual rate of progression from CC to
HCC in presence of resistance
LAM; ADF 0.0000 Conservative assumption
Annual rate of progression from DCC to HCC 0.0710 From Lin X et al. 2005 [19]*
Annual rate of progression from Seroconversion or
HBV response to death
Life table values From age-speciﬁc life tables [28]
Annual rate of progression from CHB to death 0.0060 From Lin X et al. 2005 [19]*
Annual rate of progression from CC to death 0.0540 From Lin X et al. 2005 [19]*
Annual rate of progression from DCC to death 0.1630 From Lin X et al. 2005 [19]*
Annual rate of progression from HCC to death 0.4300 From Lin X et al. 2005 [19]*
CHB, chronic hepatitis B; CC, compensated cirrhosis; HCC, hepatocellular carcinoma; DCC, decompensated cirrhosis; LAM,
lamivudine; PEG-IFN, pegylated-interferon; ADF, adefovir; HBV, hepatitis B virus.
*Weighted average derived from Lin X et al. 2005 [19] (base case estimate).
Control is assumed to be as good with adefovir as
with lamivudine in those who do not develop resistance.
Derived from Liaw et al. 2004 [5] (annualized % decrease) from
increase in Child-Pugh score.
§Derived from Liaw et al. 2004 [5] (annualized % decrease).
  2007 GlaxoSmithKline
Journal compilation   2007 Blackwell Publishing Ltd
CE evaluation of CHB therapies in Singapore 755Table 2 (a) Annual HBeAg-seroconversion rates, relapse rates and resistance rates for different treatments of HBeAg-positive
CHB derived from the literature; (b) Annual HBV response rates and lack of durability of response rates for different treatments
of HBeAg-negative CHB for different treatments derived from the literature
Model input Treatment Estimate Comment
(a)
HBeAg-seroconversion rates for patients
with ALT levels >2 · ULN in the absence
of resistance
No treatment/placebo 0.1020 Derived from Perrillo et al. 2002 [29]
LAM 0.3070 Derived from Perillo et al. 2002 [29]*
IFN 0.2250 Derived from Perillo et al. 2002 [29]
PEG-IFN 0.2660 From Lau et al. 2005 [17]
ADF 0.1520 Derived from Marcellin et al. 2002 [30]

HBeAg-seroconversion lack of durability
(% who relapse back to CHB state)
LAM 0.1020 Derived from Dienstag et al. 2003 [26]

No treatment; IFN 0.1020 From Crowley et al. 2002 [16]
PEG-IFN 0.0440 Derived from Lau et al. 2005 [17]
§
ADF 0.0800 From Chang et al. 2004 [27]
–
Emergence of resistance during treat-
ment
LAM 0.2570 Derived from the cumulative rates given
in Lai et al. 2003 [10]**
No treatment; IFN & PEG-IFN 0.0000
ADF 0.0640 Derived from the cumulative rates given
in Locarnini 2005 [31] (Adefovir mono-
therapy trials)

(b)
HBV response rates for patients with ALT
levels >2 · ULN in the absence of
resistance
No treatment/placebo 0.0000 Hadziyannis et al. 2003 [32]
LAM 0.8950 From Marcellin et al. 2004 [18]

PEG-IFN 0.6330 Marcellin et al. 2004 [18]
ADF 0.5120 Hadziyannis et al. 2003 [32]
§§
Annual lack of durability of response
(% who relapse back to CHB state)
LAM 0.9030 Derived from Marcellin et al. 2004 [18]
& Hadziyannis et al. 2005 [33]
No treatment 0.9030 Derived from Marcellin et al. 2004 [18]
& Hadziyannis et al. 2005 [33]
PEG-IFN 0.6960 Marcellin et al. 2004 [18]
ADF 0.9030 Derived from Marcellin et al. 2004 [18]
& Hadziyannis et al. 2005 [33]
CHB, chronic hepatitis B; ALT, aminotransferase; LAM, lamivudine; PEG-IFN, pegylated-interferon; ADF, adefovir; HBV,
hepatitis B virus.
*Annual HBeAg-seroconversion rate ¼ 25.4% based on all patients with ALT levels ‡2 · ULN, which is equivalent to an
annual seroconversion rate ¼ 30.7% in those without resistance and 10.2% in those with resistance. Assumption: These rates
remain constant with time.
Annual HBeAg-seroconversion rate ¼ 14.9% based on all patients with ALT levels ‡2 · ULN,
which is equivalent to an annual seroconversion rate ¼ 15.2% in those without resistance and 10.2% in those with resistance.
Assumption: These rates remain constant with time.
Assumption: % relapse rate per year is average of that occurring over
years 1–3 after stopping treatment.
§The annual rate of loss of HBeAg seroconversion for LAM was 10.2% (derived from
Dienstag et al. 2003) [26]. Therefore, the corresponding estimate for PEG-IFN would be 10.2% · (18.1/41.8) ¼ 4.4%, where
18.1% and 41.8% were the 6-month seroreversion rates obtained for PEG-IFN and LAM, respectively (Lau et al. 2005) [17].
–Baseline ALT levels unknown. **Assumption: Resistance rates for years 1–5 is the average of that observed over years 1–4.
Assumption: Resistance rate is zero for year 1. The annual resistance rate estimate (6.4%) for years 2–5 is the average of that
observed over years 2–4.
The rate of HBV DNA suppression is 73.5% after 1-year treatment with LAM. In the same study
YMDD variants occurred in 17.9% after 1 year. Therefore, the corresponding rate in the absence of resistance ¼ [0.735/
(1)0.179)] ¼ 89.5%, assuming loss of suppression in those with resistance. Assumption: Annual response rate for years 2–5
in the absence of resistance is the same as for year 1.
§§Assumption: Annual response rate for ADF in the absence of resistance
for years 2–5 is the same as for year 1.
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Disease progression in the presence of treatment
Short-course therapy with a-interferon, or 1-year treatment
with pegylated interferon a-2a, adefovir, or lamivudine had
limited impact on disease progression (Fig. 3a for HBeAg-
positive CHB and Fig. 3b for HBeAg-negative CHB).
In contrast, both lamivudine plus adefovir as rescue medica-
tion or adefovir plus lamivudine as rescue medication
administered for up to 5 years substantially decrease the rate
ofdiseaseprogression.Forexample,attheendofthetreatment
phase the proportion of the HBeAg-positive cohort that had
developed complications had been reduced by approximately
70% in those receiving these therapies (Fig. 4a). The corres-
pondingimpactondiseaseprogressionintheHBeAg-negative
cohort is shown in Fig. 4b. A comparison of these ﬁgures
shows that disease progression occurred at a faster rate in
HBeAg-negative patients than in HBeAg-positive patients.
Outcomes, costs, cost-effectiveness of treatment
alternatives
The discounted incremental costs, beneﬁts and cost-effect-
iveness ratios (ICERs) for treatment alternatives compared
with no treatment and lamivudine 1-year are given in
Tables 5a and 6a, respectively, for patients with HBeAg-
positive CHB, and Tables 5b and 6b, respectively, for patients
with HBeAg-negative CHB. (Similar results were obtained in
the absence of discounting).
A cost-effectiveness threshold of approximately S$ 53 000
was estimated for Singapore based on an international cost-
effectiveness threshold of US$ 50 000 per QALY and after
Table 3 Annual drug acquisition costs (2005)
Drugs Annual acquisition costs
(wholesale) of drugs ($S)
LAM 2774.00
ADF 3606.20
IFN* 7329.75
PEG-IFN
 20 740.00
LAM, lamivudine; PEG-IFN, pegylated-interferon; ADF, ade-
fovir.
*IFN costs are the average for Roferon-A and Intron-A
(range of doses) and 6–12 months treatment durations.
PEG-IFN costs are the average of those for Pegasys and Peg-
Intron for a duration of 12 months.
Table 4 Disease health state utilities de-
rived from the literature and the effect of
antiviral resistance
Health state utility Estimate Source
Seroconversion 0.783 From Crowley et al. 2002 [16]
CHB Untreated ¼ 0.692
LAM ¼ 0.692*
ADF ¼ 0.692*
IFN ¼ 0.467
PEG-IFN ¼ 0.5795

Adapted from Crowley et al. 2002 [16]
CC 0.561 From Crowley et al. 2002 [16]
DCC 0.150 From Crowley et al. 2002 [16]
HCC 0.118 From Crowley et al. 2002 [16]
Resistant CHB Untreated ¼ 0.692
LAM ¼ 0.692
ADF ¼ 0.692
IFN ¼ 0.467
PEG-IFN ¼ 0.5795
Adapted from Crowley et al. 2002 [16]

Resistant CC 0.561 From Crowley et al. 2002 [16]

Resistant DCC 0.150 From Crowley et al. 2002 [16]

Resistant HCC 0.118 From Crowley et al. 2002 [16]

CHB, chronic hepatitis B; CC, compensated cirrhosis; DCC, decompensated cir-
rhosis; HCC, hepatocellular carcinoma; LAM, lamivudine; ADF, adefovir; PEG-IFN,
pegylated-interferon.
Assumptions
*LAM and ADF are well tolerated in CHB patients and have at least the same
utility as untreated patients.
PEG-IFN is better tolerated than IFN but less well
tolerated than LAM or ADF, resulting in a utility mid-way between that for IFN
and LAM/ADF.
No effect of resistance per se on the health state utility.
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[13,14].
In comparison with no treatment of HBeAg-positive CHB,
short-course a-interferon was not a cost-effective therapy
(Table 5a). In contrast, base-case estimates of 1-year
treatment with pegylated interferon a-2a were below the
international threshold for cost-effectiveness in both
HBeAg-positive and HBeAg-negative CHB (Table 5a,b
respectively).
Lamivudine administered for 1 year is highly cost-effective
in comparison with no treatment of both HBeAg-positive
and HBeAg-negative CHB (Table 5a,b). One-year treatment
of HBeAg-positive CHB with lamivudine resulted in better
outcomes (life years and QALYs) at lower cost than either
short-course a-interferon or 1-year treatment with adefovir.
Although pegylated interferon a-2a resulted in better out-
comes than 1-year treatment with lamivudine, it was not
cost-effective in comparison with lamivudine (Table 6a).
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Fig. 3 Short-duration treatment of
(a) HBeAg-positive chronic hepatitis B
(CHB); (b) HBeAg-negative CHB – pro-
portion of cohort in compensated cir-
rhosis (CC), decompensated cirrhosis
(DCC) or hepatocellular carcinoma
(HCC) states during each cycle.
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Fig. 4 Long-duration treatment of
(a) HBeAg-positive chronic hepatitis B
(CHB); (b) HBeAg-negative CHB – pro-
portion of cohort in compensated cir-
rhosis (CC), decompensated cirrhosis
(DCC) or hepatocellular carcinoma
(HCC) states during each cycle.
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758 L. F. Lacey & E. GaneOne-year treatment of HBeAg-negative CHB with lamivu-
dine resulted in better outcomes at lower cost than either
adefovir or pegylated interferon a-2a (Table 6b).
In comparison with treatment of CHB for 1 year with
lamivudine, longer duration antiviral therapies (lamivudine
plus adefovir as rescue medication or adefovir plus
Table 5 (a) The discounted incremental costs, beneﬁts and cost-effectiveness ratios (ICERs) for treatment alternatives in
comparison with no treatment of HBeAg-positive chronic hepatitis B (CHB); (b) The discounted ICERs for treatment alter-
natives in comparison with no treatment of HBeAg-negative CHB
Treatment alternatives Cost (S$)
Life year
gained QALY
Cost per Life Year
gained (S$/LY)
Cost per QALY
gained (S$/QALY)
(a)
IFN 6818.65 0.273 0.110 24 952.35 61 940.92
PEG-IFN (1 year) 19 216.05 0.566 0.570 33 977.06 33 718.47
Lamivudine (1 year) 2247.74 0.324 0.319 6943.59 7053.58
Adefovir (1 year) 2982.83 0.275 0.298 10 830.09 9993.50
Lamivudine (5 years) 8031.34 0.644 0.631 12 476.32 12 724.48
Adefovir (5 years) 11 237.25 0.738 0.740 15 223.13 15 176.56
Lamivudine + adefovir as rescue (5 years) 8455.30 0.872 0.854 9695.47 9905.72
Adefovir + lamivudine as rescue (5 years) 10 845.16 0.805 0.813 13 472.82 13 344.85
(b)
PEG-IFN (1 year) 19 785.52 0.642 0.486 30 833.44 40 707.14
Lamivudine (1 year) 1928.59 0.625 0.568 3086.05 3393.32
Adefovir (1 year) 2863.18 0.516 0.471 5546.03 6078.79
Lamivudine (5 years) 10 807.30 1.133 1.077 9535.13 10 034.00
Adefovir (5 years) 13 471.57 1.731 1.665 7784.26 8090.25
Lamivudine + adefovir as rescue (5 years) 10 750.93 1.838 1.740 5848.71 6178.02
Adefovir + lamivudine as rescue (5 years) 13 111.95 1.887 1.816 6948.67 7218.64
Table 6 (a) The incremental costs, beneﬁts and cost-effectiveness ratios (ICERs) for treatment alternatives in comparison with
1-year course of lamivudine of HBeAg-positive chronic hepatitis B (CHB); (b) The ICERs for treatment alternatives in com-
parison with 1-year course of lamivudine of HBeAg-negative CHB
Treatment alternatives Cost (S$)
Life year
gained QALY
Cost per Life Year
gained (S$/LY)
Cost per QALY
gained (S$/QALY)
(a)
IFN 4570.91 )0.050 )0.209 nv nv
PEG-IFN (1 year) 16 968.32 0.242 0.251 70 161.69 67 540.78
Adefovir (1 year) 735.09 )0.048 )0.020 nv nv
Lamivudine (5 years) 5783.60 0.320 0.313 18 073.04 18 507.18
Adefovir (5 years) 8989.51 0.414 0.422 21 689.93 21 313.88
Lamivudine + adefovir as rescue (5 years) 6207.56 0.548 0.535 11 319.95 11 604.85
Adefovir + lamivudine as rescue (5 years) 8597.43 0.481 0.494 17 864.69 17 403.02
(b)
PEG-IFN (1 year) 17 856.93 0.017 )0.082 1 065 894.63 nv
Adefovir (1 year) 934.59 )0.109 )0.097 nv nv
Lamivudine (5 years) 8878.72 0.508 0.509 17 461.19 17 453.01
Adefovir (5 years) 11 542.99 1.106 1.097 10 439.73 10 524.11
Lamivudine + Adefovir as rescue (5 years) 8822.34 1.213 1.172 7271.76 7528.61
Adefovir + Lamivudine as rescue (5 years) 11 183.36 1.262 1.248 8861.37 8960.64
nv, alternative treatments dominated by 1-year course of lamivudine (i.e. better outcomes achieved at lower costs when
lamivudine is used).
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CE evaluation of CHB therapies in Singapore 759lamivudine as rescue medication) administered for up to
5 years were found to be highly cost-effective by interna-
tional standards in both HBeAg-positive and HBeAg-neg-
ative CHB. The base-case cost/QALY for treatment with
lamivudine plus adefovir as rescue medication for 5 years
was S$ 11 605 in HBeAg-positive CHB (Table 6a) and S$
7529 in HBeAg-negative CHB (Table 6b). These values are
only 22% and 14% of the internationally accepted cost-
effectiveness threshold value respectively. These conclu-
sions of cost-effectiveness were found to be robust to
uncertainties in model inputs as demonstrated by the sen-
sitivity analyses.
Sensitivity analyses
The following model inputs were found to have the greatest
effect on the cost-effectiveness of the longer duration anti-
viral therapies (lamivudine plus adefovir as rescue medica-
tion or adefovir plus lamivudine as rescue medication)
administered for up to 5 years in the treatment of HBeAg-
positive or HBeAg-negative CHB:
1. Discounting of costs and beneﬁts: In the base case analyses,
costs and beneﬁts were discounted at 5% per annum,
which is a conservative approach. The ICER estimates
decreased (i.e. became more cost-effective) when there
was no discounting or when only costs were discounted.
2. Rates of disease progression: When the maximum rates of
disease progression obtained from Lin et al. (2005) [19]
were used, particularly for the rate of progression from
CHB to CC, the ICER estimates decreased. Higher ICER
estimates were obtained when minimum rates of disease
progression were used.
3. Treatment effects: The following elements of treatment
effect were investigated individually and in combination
by increasing these model inputs by a magnitude of 25%
or decreasing them by 20%:
– Annual seroconversion rates (HBeAg-positive CHB) or
annual HBV response rates (HBeAg-negative CHB)
– Annual seroreversion rates (HBeAg-positive CHB) or
annual rate of loss of HBV response (HBeAg-negative
CHB)
– Annual antiviral resistance rates
– Magnitude of treatment reductions on the rates of disease
progression in those patients who do not achieve HBeAg-
seroconversion(HBeAg-positiveCHB)orwhodonothave
a positive HBV treatment response (HBeAg-negative
CHB). The biggest effect on the ICER estimates occurred
when varying the magnitude of treatment reduction on
the rate of disease progression from CHB to CC.
4. Health state utilities: A 25% increase in health state
utilities resulted in a 20% decrease in the ICER estimates,
whereas a 20% decrease in health state utilities resulted
in a 25% increase in ICER estimates.
5. Healthcare costs (for the different health states and CHB
antiviral drug costs): A 25% increase in healthcare costs
resulted in a 25% increase in the ICER estimates, whereas
a 20% decrease in healthcare costs resulted in a 20%
decrease in ICER estimates.
The minimum, base-case and maximum estimated ICERs
for lamivudine plus adefovir as rescue medication admin-
istered for up to 5 years in the treatment of HBeAg-positive
or HBeAg-negative CHB are shown in Fig. 5a. The corre-
sponding estimated ICERs for adefovir plus lamivudine as
rescue medication for up to 5 years are shown in Fig. 5b.
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Effectiveness and cost-effectiveness of 5-year antiviral
treatment
In comparison with no treatment (Table 5a,b), the most
cost-effective short-course treatment for CHB is lamivudine,
administered for 1 year. However, short-course and 1-year
CHB therapies have limited impact on disease progression
(Fig. 3a,b).
In contrast to short-course and 1-year CHB treatment
options, lamivudine plus adefovir as rescue medication or
adefovir plus lamivudine as rescue medication, administered
for up to 5 years, substantially decreased the rate of disease
progression in both HBeAg-positive and HBeAg-negative
CHB (Fig. 4a,b). Furthermore, by reducing the rates of dis-
ease progression, 5-year antiviral treatments decrease non-
drug healthcare costs, partially off-setting the antiviral drug
acquisition costs. As a result, in comparison with no treat-
ment or treatment with lamivudine for 1-year, both lami-
vudine plus adefovir as rescue medication or adefovir plus
lamivudine as rescue medication administered for up to
5 years are highly cost-effective, with lamivudine plus ade-
fovir as rescue medication having the lowest cost per QALY
(Tables 5a,b and 6a,b respectively).
Choice of antiviral treatment regimen
Although lamivudine plus adefovir as rescue medication had
a lower cost per QALY than adefovir plus lamivudine as
rescue medication in both HBeAg-positive CHB (Tables 5a &
6a) and HBeAg-negative CHB (Tables 5b & 6b), both regi-
mens were highly cost-effective by international standards.
Therefore, physicians have a choice as to which antiviral
treatment option to use in the long-term management of
their CHB patients. Initiating patients with adefovir therapy
has the clinical advantage of a lower risk of resistance
emerging, especially in the early stages of treatment,
whereas lamivudine has a lower acquisition drug cost for
those patients of more modest means who need to pay out of
pocket for their medication.
Comparisons with other CHB economic evaluations
Crowley et al. (2002) [16] found that antiviral treatment
(lamivudine) for 4 years was an economically dominant
strategy compared with no treatment or short-duration
treatment with a-interferon. However, the analysis by
Crowley et al. (2002) [16] was limited in so far as the
evaluation only included patients with HBeAg-positive CHB
and there was a failure to take into account the emergence
of anti-viral resistance during therapy.
Kanwal et al. (2005) [20] used a Markov model incor-
porating the emergence of antiviral resistance to evaluate
the cost-effectiveness of alternative CHB treatment strategies.
Their economic evaluation concluded that lamivudine plus
adefovir as rescue (salvage) therapy may be highly
cost-effective across most healthcare settings. The main
differences between the economic modelling performed by
Kanwal et al. (2005) [20] and the present evaluation are:
1. The price differential between adefovir and lamivudine is
much greater in the US than in Singapore (i.e. an
approximate 250% increase vs a 30% increase in the
acquisition cost of adefovir in comparison with lamivu-
dine respectively) or in other Asian countries.
2. The present study investigated antiviral treatment of CHB
for up to 5 years in comparison with life-time treatment.
This reduced the extent of assumptions that needed to be
made concerning treatment effectiveness and rates of
emergence of anti-viral resistance beyond those observed
in clinical trials.
These differences may partly explain why Kanwal et al.
(2005) [20] concluded that a-interferon might be most
cost-effective in healthcare systems with tight budgetary
constraints and with a high prevalence of HBeAg-negative
disease. However as pointed out by Weitzman and Jacobson
(2005) [21], a-interferon treatment is equivalent to a do
nothing strategy for more than 70% of patients. In contrast,
the present evaluation found that short-course a-interferon
was not cost-effective in HBeAg-positive CHB. However,
when compared with no treatment, 1-year treatment with
pegylated interferon a-2a was below the international
threshold for cost-effectiveness in both HBeAg-positive and
HBeAg-negative CHB (Tables 5a & 6a).
Sullivan et al. (2006) [22] evaluated the cost-effectiveness
of 1-year treatment with pegylated interferon a-2a compared
with 1-year lamivudine in HBeAg-positive CHB from the
perspective of the Taiwan Bureau of Nation Health Insur-
ance. They concluded that pegylated interferon a-2a provi-
ded QALY gains at a favourable cost-effectiveness ratio.
Sullivan et al. (2006) [22] used a Markov model structure
that was similar to that of Crowley et al. (2000) [15], i.e.
emergence of anti-viral resistance was not included. When
we repeated the economic evaluation using the present
model based on Taiwanese drug acquisition and healthcare
costs, similar results and conclusions were obtained to those
of Sullivan et al. (2006) [22]. Thus, conclusions of
cost-effectiveness cannot be extended from one country to
another without performing a country-speciﬁc economic
evaluation. In addition, our analysis found that up to
5 years treatment with lamivudine and adefovir as rescue
therapy provided better outcomes at lower cost than
pegylated interferon a-2a in Taiwan.
We also conducted threshold analyses to estimate the
acquisition cost in Singapore that would be required for
pegylated interferon a-2a to achieve a similar cost per QALY
(in comparison with no treatment) to that achieve with long
duration sequential antiviral therapies. In HBeAg-positive
CHB, the acquisition cost of pegylated interferon a-2a would
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effective as adefovir plus lamivudine as rescue medication for
up to 5 years and by 65% to be as cost-effective as lamivu-
dine plus adefovir as rescue medication. In HBeAg-negative
CHB, the acquisition cost of peg-IFN would need to be de-
creased by approximately 80% to be as cost-effective as the
long-duration sequential antiviral therapies.
Study limitations
The economic evaluation was limited to CHB patients, with
elevated ALT levels at least twice upper limit of normal and
who, on initiation of treatment, did not have cirrhosis or
HCC. If patients with lower baseline ALT levels or advanced
liver disease were included, it might be expected that the
beneﬁts of long-duration nucleoside analogue therapies over
both short-term therapies including interferons, would be
further enhanced given that high pre-treatment levels of
ALT is a predictive factor for end-of-treatment response and
interferons are contra-indicated in patients with DCC [23].
There was limited published data on the annual loss of
response following treatment with pegylated interferon a-2a.
More recently, longer duration post-treatment data have
been published as abstracts. Lau et al. (2006) [24] appeared
to provide a 12-month seroreversion rate in HBeAg-positive
patients of 9% (n ¼ 6/69) for pegylated interferon a-2a. This
compares with our derived estimate of 4.4%. As Lau et al.
(2006) [24] referred to relapse/no response, there is reason
to suspect that an estimate of 9% would be an over-estimate.
Moreover, a seroreversion rate of 4.4% would favour peg-
ylated interferon a-2a in comparison with antiviral treat-
ment alternatives. Marcellin et al. (2006) [25] provided 6- to
24-month post-treatment data in HBeAg-negative patients.
However, the HBV response data were based on a HBV–DNA
cut-off of 100 000 copies/mL level. This is much higher
than the threshold for not-detectable HBV-DNA used for the
comparative treatments (300–400 copies/mL) and hence
these data from Marcellin et al. (2006) [25] could not be
used in the model.
Another limitation of the present economic evaluation is
that patient adherence during long-term antiviral treatment
in the real-world setting may be worse than occurred in the
adefovir and lamivudine clinical trials. A lower level of
adherence may be expected to decrease the rate of HBeAg
seroconversion or HBV treatment response, and decrease the
magnitude of treatment effect on disease progression.
Nonetheless, it would require the choice of pessimistic esti-
mates across several variables before there would be any real
uncertainty as to the cost-effectiveness of 5-year antiviral
treatment with adefovir or lamivudine as rescue medication
in comparison with no treatment or 1-year treatment with
lamivudine, in both HBeAg-positive and HBeAg-negative
CHB.
This economic evaluation pertains speciﬁcally to Singa-
pore. However, given the highly cost-effective conclusions in
relation to 5-year antiviral therapies in both HBeAg-positive
and HBeAg-negative CHB, these conclusions might be
applicable to other countries that have similar ratios of an-
nual antiviral acquisition costs to the healthcare costs of
managing the complications of disease progression. How-
ever, country-speciﬁc economic evaluations would be re-
quired to conﬁrm this.
This economic evaluation only included direct healthcare
costs. However, if indirect costs (such as productivity losses
for time off work due to CHB-related sickness) had been ta-
ken into account, it would be expected that the cost-effect-
iveness of long-duration antiviral therapies from a societal
perspective would be further enhanced.
Lastly, newer anti-viral treatments, such as entecavir,
sequential interferon/antiviral based-strategies and combi-
nation lamivudine plus adefovir as initial therapy, were not
investigated in this economic evaluation.
CONCLUSIONS
1. In Singapore, antiviral treatment of CHB with lamivudine
or adefovir for up to 5 years using the alternative antiviral
agent as rescue medication (upon emergence of anti-viral
drug resistance) is predicted to substantially decrease the
rate of disease progression at the end of the treatment
period, in both HBeAg-positive and HBeAg-negative CHB.
By reducing the rates of disease progression, 5-year
antiviral treatments decrease non-drug healthcare costs,
partially off-setting the antiviral drug acquisition costs.
2. In Singapore, antiviral treatment of CHB with lamivudine
or adefovir for up to 5 years using the alternative
antiviral agent as rescue medication was found to be
highly cost-effective, in comparison with no treatment or
1-year treatment with lamivudine, in both HBeAg-pos-
itive and HBeAg-negative CHB, with lamivudine and
adefovir as rescue medication being the most cost-
effective strategy.
3. Sensitivity analyses indicate that these economic conclu-
sions are robust to uncertainties in model inputs.
4. Combination therapy was only considered for rescue of
patients who had developed resistance to either lamivu-
dine or adefovir monotherapy. Further studies should
include combination lamivudine plus adefovir as initial
therapy. Moreover, newer antiviral treatments such as
entecavir and other sequential treatment strategies (e.g.
using interferons and antivirals) should be evaluated.
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Appendix 1
Assumptions for model inputs
Model input Treatment Assumption
HBeAg-seroconversion rates for patients
with ALT levels ‡2 · ULN
Lamivudine Annual seroconversion rate for years 2–5 is the
same as for year 1 in the absence of resistance
Adefovir Annual seroconversion rate for years 2–5 re-
mains constant in the absence of resistance
HBeAg-seroconversion lack of durability (%
who relapse back to CHB state)
Lamivudine % Relapse rate per year is average of the an-
nual rates occurring over years 1–3 after
stopping treatment (from Dienstag et al. 2003
[26]). The rate of relapse does not change with
time
IFN From Crowley et al. 2002 [16], relapse rates
are assumed to be the same for IFN and lami-
vudine. The rate of relapse does not change
with time
PEG-IFN Derived from Dienstag et al. 2003 [26] and Lau
et al. 2005 [17]
Adefovir From Chang et al. 2004 [27], baseline ALT
levels unknown. Therefore, assuming that ALT
levels ‡2 · ULN. The rate of relapse does not
change with time
HBV response rates for patients with ALT
levels >2 · ULN
Lamivudine Annual response rate for years 2–5 in the ab-
sence of resistance is the same as for year 1
Adefovir Annual response rate for adefovir in the ab-
sence of resistance for years 2–5 is the same as
for year 1
Annual lack of durability of HBV response
(% who relapse back to CHB state)
All treatments The annual rate of relapse does not change
with length of time post-treatment
Emergence of resistance during treatment Lamivudine Resistance rates for years 1–5 is the average of
the annual rates occurring over years 1–4.
IFN/PEG-IFN No resistance occurs during treatment
Adefovir Resistance rate for years 2–5 is the average of
the annual rates occurring over years 2–4.
There is no resistance in year 1
Annual rate of progression from CHB to CC
for those who do not seroconvert or have
HBV response
In absence of treatment Rate used is applicable to Singaporeans
% Decrease in rate of progression from CHB
to CC in the absence of resistance
Lamivudine For years 2–5 it is assumed that control is
maintained in those who do not develop
resistance
IFN/PEG-IFN It is assumed that the direct effect of IFN/PEG-
IFN on disease progression during treatment is
the same as for lamivudine
Adefovir Assumes that control is as good with adefovir
as with lamivudine in those who do not de-
velop resistance
% Decrease in rate of progression from CHB
to CC in presence of resistance
All treatments Assumption of no effect
Annual rate of progression from CHB to
HCC
In absence of treatment Rate used is applicable to Singaporeans
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(Continued)
Model input Treatment Assumption
% Decrease in rate of progression from
CHB to HCC in presence of resistance
All treatments Assumption of no effect
Annual rate of progression from CC to
DCC
In absence of treatment Rate used is applicable to Singaporeans
% Decrease in rate of progression from
CC to DCC in absence of resistance
Lamivudine Increase in Child-Pugh score is indicative of
progression to DCC.
IFN/PEG-IFN It is assumed that the effect of IFN/PEG-IFN
during treatment is the same as for lamivudine
Adefovir Assumes that control is as good with Adefovir
as with lamivudine in those who do not de-
velop resistance
% Decrease in rate of progression from
CC to DCC in presence of resistance
All treatments It is assumed that the effect of IFN/PEG-IFN
during treatment is the same as for lamivudine.
Annual rate of progression from CC to
HCC
In the absence of treatment Rate used is applicable to Singaporeans
% Decrease in rate of progression from
CC to HCC in absence of resistance
Lamivudine For years 2–5, it is assumed that control is
maintained in those who do not develop
resistance
IFN/PEG-IFN It is assumed that the effect of IFN/PEG-IFN
during treatment is the same as for lamivudine
Adefovir It is assumed that control is as good with
adefovir as with lamivudine in those who do
not develop resistance
% Decrease in rate of progression from
CC to HCC in presence of resistance
All treatments Assumption of no effect
Annual rate of progression from DCC to
HCC
In the absence of treatment Rate used is applicable to Singaporeans
Annual rate of progression from sero-
conversion or HBV response to death
Life table values
(Singapore 2001)
From age-speciﬁc life tables
Annual rate of progression from CHB to
death
In the absence of treatment Rate used is applicable to Singaporeans
Annual rate of progression from CC to
death
In the absence of treatment Rate used is applicable to Singaporeans
Annual rate of progression from DCC to
death
In the absence of treatment Rate used is applicable to Singaporeans
Annual rate of progression from HCC to
death
In the absence of treatment Rate used is applicable to Singaporeans
Annual acquisition costs (wholesale) of
drugs
All treatments IFN costs are average for Roferon-A and In-
tron-A and 6–12 months treatment durations.
PEG-IFN costs are the average of those for
Pegasys and Peg-Intron for a duration of
12 months
Annual cost following HBeAg-serocon-
version (S$)
In the absence of treatment Not available from Li et al. 2004 [6]. Assumed
that the annual costs are 50% of the cost of
CHB (from Crowley et al. 2002) [16]
Utility for CHB All treatments Lamivudine and adefovir are well tolerated in
CHB patients and have at least the same utility
as untreated patients.
PEG-IFN is better tolerated than IFN but less
well tolerated than lamivudine or adefovir,
resulting in a utility mid-way between that for
IFN and lamivudine/adefovir
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(Continued)
Model input Treatment Assumption
Utility for resistant CHB All treatments No effect of resistance per se on the health state utility
For other assumptions refer to those for Utility for CHB
Utility for resistant CC Irrespective of treatment No effect of resistance per se on the health state utility
Utility for resistant DCC Irrespective of treatment No effect of resistance per se on the health state utility
Utility for resistant HCC Irrespective of treatment No effect of resistance per se on the health state utility
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